Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Superparamagnetic iron oxide: pharmacokinetics and toxicity.

R Weissleder1, D D Stark, B L Engelstad

  • 1Department of Radiology, Massachusetts General Hospital, Boston.

AJR. American Journal of Roentgenology
|January 1, 1989
PubMed
Summary

This study evaluated AMI-25, a superparamagnetic iron oxide, for its pharmacokinetics and toxicity. AMI-25 demonstrated good bioavailability and no significant toxicity, indicating its potential as a safe MRI contrast agent.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.

Journal of viral hepatitis·2016
Same author

Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network.

Journal of viral hepatitis·2016
Same author

Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin.

Alimentary pharmacology & therapeutics·2013
Same author

Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy.

Alimentary pharmacology & therapeutics·2010
Same author

Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol.

Alimentary pharmacology & therapeutics·2008
Same author

Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy.

British journal of cancer·2008

Area of Science:

  • Biomedical engineering
  • Radiology
  • Pharmacology

Background:

  • Superparamagnetic iron oxide nanoparticles are used as MRI contrast agents.
  • AMI-25 is a novel superparamagnetic iron oxide preparation undergoing clinical trials.
  • Understanding its pharmacokinetic and toxicity profile is crucial for clinical application.

Purpose of the Study:

  • To evaluate the pharmacokinetics (distribution, metabolism, bioavailability, excretion) of AMI-25.
  • To assess the toxicity (acute, subacute, mutagenicity) of AMI-25.
  • To determine the potential of AMI-25 as an MRI contrast agent.

Main Methods:

  • 59Fe radiotracer studies in rats to track iron distribution and clearance.
  • Measurements of relaxation times to assess MRI contrast effects.

Related Experiment Videos

  • Evaluation of iron deficiency anemia reversal and bioavailability.
  • Histologic examination and laboratory parameters for toxicity assessment in rats and dogs.

    • Main Results:

    • AMI-25 rapidly sequestered in the liver and spleen, with slow iron clearance and incorporation into hemoglobin.
    • The T2 effect in liver and spleen resolved faster than iron clearance, suggesting iron metabolism.
    • AMI-25 corrected iron deficiency anemia and showed comparable bioavailability to existing IV iron preparations.
    • No acute or subacute toxicity was observed even at doses 150 times the proposed MR imaging dose.

    Conclusions:

    • AMI-25 exhibits favorable pharmacokinetic properties and a high safety profile.
    • The preparation is biocompatible and effectively reverses iron deficiency anemia.
    • AMI-25 shows significant potential as a safe and effective MRI contrast agent.